<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760496</url>
  </required_header>
  <id_info>
    <org_study_id>2020-002640-23</org_study_id>
    <nct_id>NCT04760496</nct_id>
  </id_info>
  <brief_title>Effect of Increased Oxytocin Doses on the Mode of Delivery in Obese Primiparous Women With Spontaneous Labour.</brief_title>
  <acronym>PROXYMA</acronym>
  <official_title>Effect of Increased Oxytocin Doses on the Mode of Delivery in Obese Primiparous Women With Spontaneous Labour. A Double-blind, Randomised, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rate of caesarean section is higher among obese pregnant women, leading to increased&#xD;
      morbidity in this already vulnerable population. Oxytocin is the main drug used in obstetrics&#xD;
      to optimize progress of labour, but observational studies have suggested that its efficiency&#xD;
      may be insufficient in obese women with usual doses.&#xD;
&#xD;
      The research is a randomised controlled trial to test the effect of an increased oxytocin&#xD;
      dose on the rate of caesarean section in obese primiparous women with spontaneous labour&#xD;
      between two oxytocin dosage regimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis underlying this trial is that an increase in oxytocin dose can reduce the rate&#xD;
      of caesarean sections in primiparous obese patients, with a spontaneous onset of labour,&#xD;
      without increasing maternal or neonatal morbidity. This would be a major step forward in&#xD;
      reducing morbidity in an at-risk population and in improving the obstetric prognosis for&#xD;
      future pregnancies.&#xD;
&#xD;
      The research is a double-blind controlled trial, including primiparous obese women in&#xD;
      spontaneous labour, for whom a prescription of oxytocin is decided. Oxytocin is currently&#xD;
      indicated for notably &quot;insufficiency of uterine contractions, at the beginning or during&#xD;
      labour&quot;.The recommended dosage in the market authorization will be used for the control&#xD;
      group.&#xD;
&#xD;
      The control group will receive oxytocin at 2 milli-International unit /mL and the&#xD;
      intervention group at 4 milli-International unit /mL, controlled by pump (final volume = 500&#xD;
      mL) or electrical syringe (final volume = 50 mL).&#xD;
&#xD;
      The primary objective is to compare the effect of higher doses of oxytocin (intervention&#xD;
      group) vs standard doses of oxytocin (control group) on the rate of caesarean sections in&#xD;
      obese patients with spontaneous onset of labour.&#xD;
&#xD;
      The secondary objectives will be to compare the effect of higher doses of oxytocin&#xD;
      (intervention group) vs standard doses of oxytocin (control group) on maternal and labour&#xD;
      complications (length of labour, arrest of labour, interruption of oxytocin perfusion and&#xD;
      reason, uterine hyper-stimulation, mode of vaginal delivery, reason for caesarean section,&#xD;
      post-partum haemorrhage, maternal blood transfusion, volume of oxytocin infusion, oxytocin&#xD;
      side effects), as well as foetal complications and neonatal complications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>There is two group of patient for which the prescription of oxytocin is required for the care :&#xD;
the control group will receive will receive oxytocin at 2 mIU/mL (standard dose) the experimental group will receive oxytocin at 4 mIU/mL</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>An &quot;out-of-protocol&quot; healthcare professional (midwife / nurse) will prepare oxytocin. The &quot;out-of-protocol&quot; healthcare professional (midwife / nurse) will not be a study's investigator, and will not be involved in the patient's care. The randomization group will not be communicated to the investigator or any medical personnel involved in the study or patient by the &quot;out-of-protocol&quot; nurse/midwife, in order to preserve the double-blind design.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of caesarean section during labour</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>The decision of caesarean section is made by the responsible obstetrician in charge of the patient, he or she will be blinded of the patient's group (oxytocin dosage) to avoid differential indication for caesarean section.&#xD;
Therefore, the decision to perform (or not) a caesarean section will be only based on foetal/maternal criteria, independently of oxytocin dosage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of labour phases</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Length of labour phases is measured in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrest of labour</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>It will be evaluated if there is two or more hours without cervical dilation (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interruption of oxytocin perfusion and causes</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Interruption of oxytocin perfusion (yes/no) and causes (foetal heart anomalies / uterine hyperkinesia / uterine hypertonia / other)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine hyper-stimulation</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Uterine hyper-stimulation (more than 5 uterine contractions per 10 min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mode of vaginal delivery</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Spontaneous or operative delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for the caesarean section</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>foetal heart anomalies / labour arrest / other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-partum haemorrhage</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Post-partum haemorrhage (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal blood transfusion</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Maternal blood transfusion (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of oxytocin infusion</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Volume of oxytocin infusion (mL/H)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxytocin side effects</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>nausea, vomiting, headaches, increased or decreased heart rate, allergic reaction, skin rash</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">882</enrollment>
  <condition>Obese</condition>
  <condition>Primiparous Women</condition>
  <condition>Oxytocin</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will receive oxytocin at 4 mIU/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will receive oxytocin at 2 mIU/mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin 4 mIU/mL</intervention_name>
    <description>Oxytocin at 4 mIU/mL administrated by IV infusion controlled by pump or electric syringe.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin 2 mIU/mL</intervention_name>
    <description>Oxytocin at 2 mIU/mL administrated by IV infusion controlled by pump or electric syringe.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        Inclusion criteria are the following:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Nulliparous&#xD;
&#xD;
          -  BMI ≥ 30 kg/m² at the beginning of pregnancy&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Spontaneous onset of labour&#xD;
&#xD;
          -  Cephalic presentation&#xD;
&#xD;
          -  Term ≥ 37 weeks of gestation and &lt; 42 weeks of gestation&#xD;
&#xD;
          -  Medical Indication and absence of medical contraindication for oxytocin during labour:&#xD;
             inadequate and/or ineffective uterine contraction and/or delayed cervical dilation&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
          -  Affiliation to a french social security system&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        Exclusion criteria are the following:&#xD;
&#xD;
          -  Hypersensitivity to the active substance (oxytocin), to any of its excipients or to&#xD;
             latex (risk of cross allergy)&#xD;
&#xD;
          -  Medical contraindication for oxytocin&#xD;
&#xD;
          -  Coagulation disorders&#xD;
&#xD;
          -  Foetal growth restriction (inferior to 5th percentile)&#xD;
&#xD;
          -  Foetal malformations&#xD;
&#xD;
          -  Foetal heart rate anomalies before the use of oxytocin&#xD;
&#xD;
          -  History of uterine surgery&#xD;
&#xD;
          -  Patient with a disease requiring induction of labour or caesarean section prior to&#xD;
             labour&#xD;
&#xD;
          -  Severe renal failure&#xD;
&#xD;
          -  Patient deprived of their liberty (under curator or guardianship)&#xD;
&#xD;
          -  Participation in another interventional trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexandra BENACHI, PHD, MD</last_name>
    <phone>+33145374476</phone>
    <email>alexandra.benachi@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie CARRARA, MD</last_name>
    <phone>+33145374441</phone>
    <email>Julie.carrara@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lionel CARBILLON</last_name>
    </contact>
    <investigator>
      <last_name>Lionel CARBILLON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux (Pellegrin)</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Loic SENTILHES</last_name>
    </contact>
    <investigator>
      <last_name>Loic SENTHILES</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Béclère</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandra BENACHI, PHD, MD</last_name>
      <phone>+33145374476</phone>
      <email>alexandra.benachi@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Julie CARRARA, MD</last_name>
      <phone>+33145374441</phone>
      <email>Julie.carrara@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Alexandra BENACHI, PHD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Luc RIGONNOT</last_name>
    </contact>
    <investigator>
      <last_name>Luc RIGONNOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne-Gaêl CORDIER</last_name>
    </contact>
    <investigator>
      <last_name>Anne-Gaêl CORDIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Charles GARABEDIAN</last_name>
    </contact>
    <investigator>
      <last_name>Charles GARABEDIAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Florent FUCHS</last_name>
    </contact>
    <investigator>
      <last_name>Florent FUCHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Vincent LETOUZEY</last_name>
    </contact>
    <investigator>
      <last_name>Vincent LETOUZEY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bichat Claude Bernard</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Dominique LUTON</last_name>
    </contact>
    <investigator>
      <last_name>Dominique LUTON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin Port Royal</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Camille LE RAY</last_name>
    </contact>
    <investigator>
      <last_name>LE RAY Camille</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poissy St Germain</name>
      <address>
        <city>Poissy</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrick ROZENBERG</last_name>
    </contact>
    <investigator>
      <last_name>Patrick ROZENBERG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg (Hôpital de Hautepierre)</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe DERUELLE</last_name>
    </contact>
    <investigator>
      <last_name>Phillipe DERUELLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

